N4 Pharma Past Earnings Performance

Past criteria checks 0/6

N4 Pharma's earnings have been declining at an average annual rate of -0.6%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 51.2% per year.

Key information

-0.6%

Earnings growth rate

18.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate-51.2%
Return on equity-87.7%
Net Margin-18,399.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How N4 Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:0GO Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-111
31 Mar 240-111
31 Dec 230-111
30 Sep 230-110
30 Jun 230-110
31 Mar 230-110
31 Dec 220-111
30 Sep 220-111
30 Jun 220-111
31 Mar 220-111
31 Dec 210-211
30 Sep 210-211
30 Jun 210-211
31 Mar 210-211
31 Dec 200-111
30 Sep 200-111
30 Jun 200-110
31 Mar 200-110
31 Dec 190-110
30 Sep 190-110
30 Jun 190-111
31 Mar 190-111
31 Dec 180-111
30 Sep 180-111
30 Jun 180001
31 Mar 180000
31 Dec 170-100
30 Jun 170-200
31 Mar 170-100

Quality Earnings: 0GO is currently unprofitable.

Growing Profit Margin: 0GO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0GO is unprofitable, and losses have increased over the past 5 years at a rate of 0.6% per year.

Accelerating Growth: Unable to compare 0GO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0GO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Return on Equity

High ROE: 0GO has a negative Return on Equity (-87.74%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies